This company listing is no longer active
Nichi-Iko Pharmaceutical Management
Management criteria checks 0/4
Key information
Shingo Iwamoto
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | less than a year |
| Board average tenure | less than a year |
Recent management updates
Recent updates
CEO
Shingo Iwamoto
less than a year
Tenure
Shingo Iwamoto serves as Representative Director & President at Nichi-Iko Pharmaceutical Co., Ltd. since 2023.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Representative Director & President | less than a year | no data | no data | |
| Managing Executive Officer & Director | less than a year | no data | 0% ¥ 0 | |
| Senior Executive Officer & Head of Quality Assurance & Pharmacovigilance Division | no data | no data | no data | |
| Senior Executive Officer & Head of Corporate Strategy & Planning Division | no data | no data | no data | |
| Managing Executive Officer & Director | less than a year | no data | no data | |
| Managing Executive Officer & Director | less than a year | no data | 0% ¥ 0 | |
| Senior Executive Officer | no data | no data | no data | |
| Senior Executive Officer | no data | no data | no data | |
| Senior Executive Officer | no data | no data | no data | |
| Director & Senior Managing Executive Officer | less than a year | no data | 0% ¥ 0 | |
| Senior Executive Officer | no data | no data | no data | |
| Chief Executive Officer of Sagent Pharmaceuticals | no data | no data | no data |
0.8yrs
Average Tenure
62yo
Average Age
Experienced Management: 4541's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Representative Director & President | less than a year | no data | no data | |
| Managing Executive Officer & Director | no data | no data | 0% ¥ 0 | |
| Managing Executive Officer & Director | less than a year | no data | no data | |
| Managing Executive Officer & Director | no data | no data | 0% ¥ 0 | |
| Director & Senior Managing Executive Officer | no data | no data | 0% ¥ 0 | |
| Executive VP & Director | 14.1yrs | no data | 0% ¥ 0 |
0.8yrs
Average Tenure
62yo
Average Age
Experienced Board: 4541's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/31 02:09 |
| End of Day Share Price | 2023/03/28 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nichi-Iko Pharmaceutical Co., Ltd. is covered by 14 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Hidemaru Yamaguchi | Citigroup Inc |
| Fumiyoshi Sakai | Credit Suisse |